The European Union's efforts in combating rare diseases reached a new milestone this October, with the 50th positive opinion on an 'orphan' medicine being adopted by the EMEA's Committee for Medicinal Products for Human Use (CHMP).
50th orphan medicine receives positive opinion
The European Union's efforts in combating rare diseases reached a new milestone this October, with the 50th positive opinion on an 'orphan' medicine being adopted by the EMEA's Committee for Medicinal Products for Human Use (CHMP).
To date, a total of 569 medicines have been awarded orphan-designation status by the European Commission, based on recommendations of the
EMEA's Committee for Orphan Medicinal Products (COMP). Of these, 50 have now been successful in obtaining a positive EMEA opinion on marketing authorisation, with many more positive opinions expected over the coming years.
Developed specifically for the diagnosis, treatment or prevention of rare diseases, these medicines have the potential to offer relief to many thousands of European citizens suffering from chronic and often debilitating diseases who would otherwise have few-if any-treatment options available.
A listing of the 50 orphan medicines to have received a positive CHMP opinion is available here:
http://www.emea.europa.eu/pdfs/human/comp/56357508en.pdf
See also: Orphan drugs and rare diseases at a glance
http://www.emea.europa.eu/pdfs/human/comp/29007207en.pdf
EMEA website section: Orphan medicinal products
http://www.emea.europa.eu/htms/human/orphans/intro.htm
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.